Everything drug pricing and policy, every day
Plus a look at an IQVIA deep dive into a way of ensuring that 340B discounts make it directly to patients: ‘340 cards’
And looking through a fresh batch of comments on CMS IRA guidance makes clear that 340B is the elephant in the room
And the reconciliation bill is headed to a Senate vote today ... but without PBM reform or orphan-drug provisions
And IQVIA data shows the extent of the utilization management headaches for Medicare patients
And introducing a new way of segmenting the voices in the 340B debate: the (Jimmy) Buffett Rule
And the remarkable ability of hospitals to drive policy conversations in the Medicaid/reconciliation debate
And a veritable deluge of data about benefit design has me thinking about the impact on PBMs ... and patients
And the latest skirmish in the pharm-to-table trend underscores the choice that telehealth providers must make around obesity meds
And I go deep on the ideological bent of Theo Merkel, one of the point people in the MFN conversations with pharma
